Olanzapine (Zyprexa Relprevv) vs Paliperidone palmitate (Invega Trinza)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Olanzapine (Zyprexa Relprevv)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00088478 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial of 402 patients. All three tested doses of the long-acting olanzapine injection produced a significantly greater reduction in psychiatric symptom severity (PANSS) than placebo.
Reported efficacy
Demonstrate superiority of IM olanzapine depot 300 mg/2 weeks, 405 mg/4 weeks, and 210 mg/2 weeks dosages compared with placebo in the treatment of patients with schizophrenia: 8-week acute study, olanzapine long-acting injection (210 mg/2wk, 300 mg/2wk, 405 mg/4wk) vs placebo: PANSS total score decrease significantly greater for all three LAI regimens vs placebo (p<.001 each). (met)
Result source: NCT00088478
Paliperidone palmitate (Invega Trinza)
Marketed by Johnson & Johnson
NCT02713282 · Phase 3 · completed
This was a single-group, open-label study without randomization or a comparator arm, so it could not directly compare the 3-month formulation with placebo or another treatment. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Number of Participants With Relapse (Up to Day 730); Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Up to Day 730): Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178 (not_applicable)
Result source: NCT04072575
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Olanzapine (Zyprexa Relprevv) | Paliperidone palmitate (Invega Trinza) |
|---|---|---|
| PANSS total, change | —Not posted · NCT00088491 | -1.8 vs -1.6vs PP3MNCT03345342 |
| CGI-S, change | -0.4 vs -0.3vs Oral OlanzapineNCT00320489 | 0 vs 0vs PP3MNCT033453422 other results
|
| PANSS response | —Not posted · NCT00088491 | —Not posted · NCT02713282 |
| PSP, change | —Not posted · NCT00088491 | 1 vs 1.1vs PP3MNCT033453422 other results
|
| Relapse (% of patients) | 20.1% vs 18.5%vs Oral OlanzapineNCT00320489 | —Not posted · NCT02713282 |
PANSS total, change
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
- Paliperidone palmitate (Invega Trinza)
- -1.8 vs -1.6vs PP3MNCT03345342
CGI-S, change
- Olanzapine (Zyprexa Relprevv)
- -0.4 vs -0.3vs Oral OlanzapineNCT00320489
- Paliperidone palmitate (Invega Trinza)
- 0 vs 0vs PP3MNCT03345342
2 other results
- -0.2 vs -0.3 NCT02431702
- -0.7 vs -0.7 NCT02431702
PANSS response
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
- Paliperidone palmitate (Invega Trinza)
- —Not posted · NCT02713282
PSP, change
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
- Paliperidone palmitate (Invega Trinza)
- 1 vs 1.1vs PP3MNCT03345342
2 other results
- 7.5 vs 7 NCT02431702
- 2.5 vs 2.9 NCT02431702
Relapse (% of patients)
- Olanzapine (Zyprexa Relprevv)
- 20.1% vs 18.5%vs Oral OlanzapineNCT00320489
- Paliperidone palmitate (Invega Trinza)
- —Not posted · NCT02713282
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. Olanzapine (Zyprexa Relprevv): 7 of 7 rows · Paliperidone palmitate (Invega Trinza): 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Olanzapine (Zyprexa Relprevv) Rows use multiple source trials | Paliperidone palmitate (Invega Trinza) Rows use multiple source trials |
|---|---|---|
| CGI-S absolute change · score No placebo or comparator arm | -0.17 score @ 313wka,b,c NCT00088465 · Phase 3 · registry result, not featured evidence | 0 score @ 104wk700 or 1000 mg eqa,b,c NCT04072575 · Phase 3 · combination |
| PANSS Total absolute change · score No placebo or comparator arm | 0.3 score @ 330wka,b,d NCT00088465 · Phase 3 · registry result, not featured evidence | 0.7 score @ 104wk700 or 1000 mg eqa,b,d NCT04072575 · Phase 3 · combination |
| Time to Relapse Median time to event · months | 17.71 vs 20.48 Oral Olanzapine months*a,b,e NCT00320489 · Phase 3 · monotherapy · converted to months from 539 days as posted | NA vs 12.98 placebo months @ 60wka,b,e NCT01529515 · Phase 3 |
| Dropout rate | 54.9%f NCT00320489 · Phase 3 · monotherapy show 1 more result60.3% NCT00088465 · Phase 3 · registry result, not featured evidence | —Double-blind PP6Mg NCT03345342 · Phase 3 · Schizophrenia · phase 3 show 6 more results—Follow-up Phase PP6M NCT03345342 · Phase 3 · Schizophrenia · phase 3 13.5%700 or 1000 mg eq NCT04072575 · Phase 3 · combination — NCT01529515 · Phase 3 —Part 2-Paliperidone Palmitate (PP) NCT02431702 · Phase 3 · registry result, not featured evidence · combination —Part 3- OAP to PP (or Delayed-Star NCT02431702 · Phase 3 · registry result, not featured evidence —Part 3-PP to PP (Extended Disease NCT02431702 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 9.8%f NCT00320489 · Phase 3 · monotherapy show 1 more result8.3% NCT00088465 · Phase 3 · registry result, not featured evidence | —Double-blind PP6Mg NCT03345342 · Phase 3 · Schizophrenia · phase 3 show 6 more results—Follow-up Phase PP6M NCT03345342 · Phase 3 · Schizophrenia · phase 3 3.9%700 or 1000 mg eq NCT04072575 · Phase 3 · combination — NCT01529515 · Phase 3 —Part 2-Paliperidone Palmitate (PP) NCT02431702 · Phase 3 · registry result, not featured evidence · combination —Part 3- OAP to PP (or Delayed-Star NCT02431702 · Phase 3 · registry result, not featured evidence —Part 3-PP to PP (Extended Disease NCT02431702 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 9.5%f NCT00320489 · Phase 3 · monotherapy show 1 more result18.3% NCT00088465 · Phase 3 · registry result, not featured evidence | 5%Double-blind PP6Mg NCT03345342 · Phase 3 · Schizophrenia · phase 3 show 6 more results5.5%Follow-up Phase PP6M NCT03345342 · Phase 3 · Schizophrenia · phase 3 4.5%700 or 1000 mg eq NCT04072575 · Phase 3 · combination 2.5% NCT01529515 · Phase 3 12.8%Part 2-Paliperidone Palmitate (PP) NCT02431702 · Phase 3 · registry result, not featured evidence · combination 5.3%Part 3- OAP to PP (or Delayed-Star NCT02431702 · Phase 3 · registry result, not featured evidence 2%Part 3-PP to PP (Extended Disease NCT02431702 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | show 1 more resultweight increased 14.4% anxiety 9.7% insomnia 9.7% NCT00088465 · Phase 3 · registry result, not featured evidence | g weight increased 8.4% injection site pain 7.7% headache 6.7% NCT03345342 · Phase 3 · Schizophrenia · phase 3 show 6 more resultsnasopharyngitis 3.7% upper respiratory tract infection 0.9% headache 0% NCT03345342 · Phase 3 · Schizophrenia · phase 3 700 or 1000 mg eq headache 13.5% blood prolactin increased 10.7% hyperprolactinaemia 7.3% NCT04072575 · Phase 3 · combination headache 8.8% (placebo 4.1%) weight increased 8.8% (placebo 3.4%) anxiety 8.1% (placebo 10.3%) NCT01529515 · Phase 3 weight increased 28.2% akathisia 9% headache 9% NCT02431702 · Phase 3 · registry result, not featured evidence · combination weight increased 15.8% anxiety 10.5% insomnia 10.5% NCT02431702 · Phase 3 · registry result, not featured evidence weight increased 14.3% insomnia 10.2% nasopharyngitis 6.1% NCT02431702 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cAssessment timepoints differ: 104 weeks versus 313 weeks.
- dAssessment timepoints differ: 104 weeks versus 330 weeks.
- eThe assessment timepoint is not available for both results.
- fPopulation comparability has not been reviewed for these studies.
- gPopulation comparability has not been reviewed for 5 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Olanzapine (Zyprexa Relprevv)
+ 11 further endpoints in the CSV export.
Paliperidone palmitate (Invega Trinza)
show 2 more results
show 1 more result
show 3 more results
show 1 more result
+ 7 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olanzapine (Zyprexa Relprevv)'s landscape · Paliperidone palmitate (Invega Trinza)'s landscape